Android app on Google Play

Repligen (RGEN) Continues Higher on Strong RG3039 Phase 1 Data

April 25, 2012 12:12 PM EDT Send to a Friend
Repligen (Nasdaq: RGEN) shares are continuing to move higher on the session Wednesday following a release earlier showing positive data from RG3039 Phase 1 as a spinal muscular atrophy (SMA) treatment. Shares are up 8 percent on the session following the release.

From the release: "The Phase 1 trial was a blinded, ascending, single dose study of RG3039 administered to 32 healthy volunteers. The study results demonstrate that RG3039 was well tolerated at all doses administered, with no serious adverse events reported."

For more color, click here.




You May Also Be Interested In


Related Categories

Insiders' Blog, Momentum Movers

Add Your Comment